Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E J Yun

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Oncogene|July 22, 2014
DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1E-J Yun, S T Baek, D Xie, et al.
Cell Death & Disease|October 30, 2015
DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosisJ Zhou, Z Ning, B Wang, et al.
Transplantation Proceedings|January 3, 2006
Benign breast diseases associated with cyclosporine therapy in renal transplant recipientsY L Seo, C S Choi, D Y Yoon, et al.
Oncogene|February 16, 2016
Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapiesJ Zhou, J Luo, K Wu, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Oncogene|July 22, 2014
DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1E-J Yun, S T Baek, D Xie, et al.
Cell Death & Disease|October 30, 2015
DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosisJ Zhou, Z Ning, B Wang, et al.
Transplantation Proceedings|January 3, 2006
Benign breast diseases associated with cyclosporine therapy in renal transplant recipientsY L Seo, C S Choi, D Y Yoon, et al.
Oncogene|February 16, 2016
Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapiesJ Zhou, J Luo, K Wu, et al.
Pageof 2